haemophilia a造句

• Haemophilia A has also been studied in gene therapy with a lentiviral vector in mice.
• "' Haemophilia A "'is a genetic deficiency in clotting factor VIII, which causes increased bleeding and usually affects males.
• A non-genetic form of haemophilia is caused by autoantibodies against factor VIII and so is known as " acquired haemophilia A ".
• In 1947, Pavlosky, a doctor from Buenos Aires, found haemophilia A and haemophilia B to be separate diseases by doing a lab test.
• Because of its importance in clotting, Factor VIII is also known as anti-haemophilic factor, and deficiencies of Factor VIII cause haemophilia A.
• In 2007, a trial comparing on-demand treatment of boys ( < 30 months ) with haemophilia A with $ 300, 000 per year.
• In both haemophilia A and B, there is spontaneous bleeding but a normal bleeding time, normal prothrombin time, normal thrombin time, but prolonged partial thromboplastin time.
• Spontaneous mutations account for about 33 % of all cases of haemophilia A . About 30 % of cases of haemophilia B are the result of a spontaneous gene mutation.
• Factor VIII is used in haemophilia A and factor IX in haemophilia B . Factor replacement can be either isolated from human blood serum, recombinant, or a combination of the two.
• Females who inherit the gene for Haemophilia A or B from both parents would be expected to manifest full symptoms, similar to those seen in affected males, but this is extremely rare.
• Some of the experimental uses for the Lentivirus vector have been in gene therapy of diseases like Diabetes mellitus, Murine haemophilia A, prostate cancer, chronic granulomatous disease, and vascular gene therapy.
• About 5-10 % of people with haemophilia A are affected because they make a dysfunctional version of the factor VIII protein, while the remainder are affected because they produced factor VIII in insufficient amounts ( quantitative deficiency ).
• Other diseases mentioned are high altitude pulmonary edema, Vogt-Koyanagi-Harada syndrome ( DRB1 * 0405, see above table for Japanese ), HIV resistance in the US, and haemophilia A ( anti-FVIII inhibitor response ).
• The vector targets the haematopoietic cells in order to increase the amount of factor VIII, which is affected in haemophilia A . But this continues to be a subject of study as the lentivirus vector was not completely successful in achieving this goal.
• "' Turoctocog alfa "'( trade name "'NovoEight "') is a recombinant antihemophilic factor VIII used for the treatment of and prophylaxis of bleeding patients with haemophilia A . It is marketed by Novo Nordisk.
• Haemophilia A, is a recessive X-linked genetic disorder resulting in a deficiency of functional clotting Factor VIII . Haemophilia C, is an autosomal genetic disorder involving a lack of functional clotting Factor XI . Haemophilia C is not completely recessive, as heterozygous individuals also show increased bleeding.